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In Brief
D’Gama et al. find more autism spectrum
disorder brains have deleterious
mutations in candidate ASD genes than
control brains, including two ASD brains
with deleterious somatic mutations.
Results suggest combinations of
germline and somatic mutations may
contribute to ASD risk.
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Single nucleotide variants (SNVs), particularly loss-
of-function mutations, are significant contributors
to autism spectrum disorder (ASD) risk. Here we
report the first systematic deep sequencing study
of 55 postmortem ASD brains for SNVs in 78 known
ASD candidate genes. Remarkably, even without
parental samples, we find more ASD brains with
mutations that are protein-altering (26/55 cases
versus 12/50 controls, p = 0.015), deleterious (16/55
versus 5/50, p = 0.016), or loss-of-function
(6/55 versus 0/50, p = 0.028) compared to controls,
with recurrent deleterious mutations in ARID1B,
SCN1A, SCN2A, and SETD2, suggesting these muta-
tions contribute to ASD risk. In several cases, the
identified mutations and medical records suggest
syndromic ASD diagnoses. Two ASD and one Fragile
X premutation case showed deleterious somatic mu-
tations, providing evidence that somatic mutations
occur in ASD cases, and supporting amodel in which
a combination of germline and/or somatic mutations
may contribute to ASD risk on a case-by-case basis.
INTRODUCTION
Autism spectrum disorder (ASD) affectsR1% of American chil-
dren and is characterized by (1) deficits in social interaction and
social communication and (2) restricted and repetitive behaviors,
interests, or activities (Wingate et al., 2014). ASD is genetically
heterogeneous, with contributions from heritable mutations—
including monogenic conditions, common variants, and rare
recessivemutations—aswell as fromde novomutations (Huguet
et al., 2013). Whereas genetic studies of ASD risk have analyzed
DNA from blood, saliva, or cell lines (De Rubeis et al., 2014; Ios-910 Neuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc.sifov et al., 2014; O’Roak et al., 2011), postmortem ASD brain
samples have been utilized mostly to study neuropathology,
transcriptomics, and splicing (Chen et al., 2015; Irimia et al.,
2014). Apart from a set of postmortem autism brain samples
analyzed for copy number variants (CNVs) (Wintle et al., 2011),
we know little of the underlying genetics of these postmortem
autism brains. Identifying pathogenic mutations in these brains
would aid genotype-phenotype correlation and interpretation
of other alterations. In addition, somatic mutations—de novo
mutations occurring postfertilization—are of growing interest in
neurodevelopmental disorders that have similarly high de novo
mutation rates to ASD, or with similar or overlapping symptoms,
and have been reported in case studies with ASD (Poduri et al.,
2013). Targeted deep sequencing allows detection of germline
and somatic mutations in developmental brain disorders, espe-
cially when brain tissue is directly analyzed (D’Gama et al.,
2015; Lee et al., 2012; Poduri et al., 2012; Rivie`re et al., 2012)
and sequence coverage is very high (Jamuar et al., 2014). We
used targeted deep sequencing of brain tissue from ASD pa-
tients and neurotypical controls to investigate genetic mecha-
nisms underlying ASD risk in these patients, including possible
contributions of somatic mutations.RESULTS
We performed ultradeep sequencing on DNA from postmortem
cerebral cortical and/or cerebellar brain samples from 55 ASD
cases, 50 neurotypical controls, and 17 cases with suspected
ASD or related diagnoses (Figure 1A; see Table S1 available on-
line). In order to achieve the high coverage necessary to sensi-
tively detect somatic mosaic mutations, we used a targeted
panel of 78 ASD candidate genes showing dominant or X-linked
inheritance (see Supplemental Experimental Procedures) (Basu
et al., 2009; Betancur, 2011; O’Roak et al., 2012). We achieved
5473 average coverage, with 95.7% of the analyzable target re-
gions covered by R100 reads and 48.2% covered by R1,000
reads, providing sensitivity to detect somatic mutations in these
Figure 1. Targeted Deep Sequencing Identifies Germline and Somatic Mutations in ASD Candidate Genes in Postmortem ASD Brain
(A) Study schematic. DNA extracted from ASD and control brain samples was sequenced at high coverage using a targeted panel of candidate ASD genes. After
variant calling and filtering, protein-altering variants were validated using Sanger sequencing and subcloning, and somatic variants were traced across the brain
and nonbrain tissues, when available.
(B) Fraction of cases and controls harboring synonymous, protein-altering, deleterious (subset of protein-altering), or loss-of-function (subset of deleterious)
variants. p values were calculated using a two-tailed Fisher’s exact test.
(C) Validation of germline and somatic variants according to total depth of sequence coverage. Essentially all germline variants validated; somatic variants were
more likely to validate at higher total depth (R1003).
(D) Validation of somatic variants according to alternate allele depth of coverage. Somatic variants were more likely to validate at alternate allele depthR253.
Each data point represents the validation fraction for all variants with (B) total or (C) alternate allele depth from the previous data point to that data point. See also
Table S1 and Tables S3–S5.genes to a level of z5% alternate allele frequency (AAF). We
identified 408 ± 69 SNVs and indels per sample and validated
all rare, high-quality, protein-altering variants (missense,nonsense, splice site, indel, and frameshift) using Sanger
sequencing; any potential somatic variants were also validated
with subcloning followed by Sanger sequencing of individualNeuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc. 911
Table 1. Deleterious Mutations in ASD and Fragile X Cases
Case Diagnosis Gene Mutation cDNA Protein Type
797 Autism ADNP Ms c.3281G>T p.G1094V Germline
AN16641 Autism ARID1B Ms c.4237C>T p.P1413S Germline
AN17515 Autism ARID1B Ms c.1463C>G p.P488R Germline
5340 Autism/Parkinson’s Disease ATP10A Ms c.622C>T p.R208W Germline
AN16641 Autism CACNA1C Ms c.3416G>A p.R1139H Germline
5006 Fragile X, premutation CACNA1C St c.2T>C (start loss) Somatic
5278 Autism CACNA1H Ms c.5909C>G p.S1970C Germline
UK28768 Autism CHD8 Ms c.2230G>A p.V744I Germline
5297 Autism GRIN2A Ms c.2650G>A p.D884N Germline
797 Autism PQBP1 Ms c.731C>T p.P244L Germline
AN01570 Autism PTEN Ns c.195C>A p.Y65* Germline
5278 Autism SCN1A Sp c.602+1G>A N/A Somatic
AN16115 Autism SCN1A Ms c.4319C>T p.A1440V Germline
4849 Autism SCN2A Ms c.2021C>A p.T674K Germline
AN04166 Autism SCN2A Ms c.5230G>A p.G1744R Germline
AN08043 Autism SCN2A Sp c.4551+1G>C N/A Germline
AN09714 Autism SCN2A Ns c.4543C>T p.R1515* Germline
1349 Autism SEMA5A Ns c.586C>T p.R196* Germline
UK20244 Autism SETD2 Ms c.4871C>G p.S1624C Somatic
AN00090 Autism/Angelman Syndrome SETD2 Ms c.1463A>G p.Y488C Germline
AN16641 Autism SLC6A8 Fs c.205_206delG p.A69Pfs*28 Germline
Details on the mutations detected in ASD and Fragile X cases that are predicted to be loss-of-function or deleterious by at least three prediction tools.
Case AN00090 also has a 15q deletion consistent with Angelman Syndrome (Wintle et al., 2011). Del, deletion; Fs, frameshift; Ms, missense; Ns,
nonsense; Sp, splicing; St, start lost. See also Figure S1 and Table S2.clones, to determinemosaicism using a technology independent
of the discovery platform.
Remarkably, despite themodest sampleofASDbrainsavailable
for sequencing, and the absence of familial samples for testing
segregation, damaging mutations were strikingly more common
in ASD brains than control brains. Overall, we identified 34 pro-
tein-altering variants in 25 genes in ASD cases and 15 protein-
altering variants in 13 genes in neurotypical controls (Table S2).
Compared to controls, significantly more ASD cases harbored
protein-altering variants (26/55 versus 12/50, p = 0.015), delete-
rious variants (16/55 versus 5/50, p = 0.016)—i.e., loss-of-function
andmissense predicted to be deleterious by at least three predic-
tion tools—and loss-of-function variants (nonsense, splice site,
and frameshift, 6/55 versus 0/50, p = 0.028), whereas functionally
neutral variantswereequally common incasesandcontrols (10/55
versus12/50, p=0.483, two-tailedFisher’s exact tests) (Figure1B;
Table S3). The excess of protein-altering variants in ASD cases
compared to controls was driven by the deleterious and particu-
larly the loss-of-function variants, consistent with previous reports
(Sanders et al., 2012). Recurrent loss-of-function and/or delete-
rious missense variants occurred in four genes (ARID1B,
SCN1A, SCN2A, and SETD2) in ASD cases (Table 1), consistent
withpreviousWholeExomeSequencing (WES) studies (DeRubeis
et al., 2014; Iossifovet al., 2014).Wealso identifiedprotein-altering
variants in cases with suspected ASD or related diagnoses (Table
S2). Although parental samples are not available to test for the de
novo nature of these variants, the large excess of deleterious var-912 Neuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc.iants in ASD brains strongly suggests that most of the deleterious
and loss-of-function variants contributed to ASD pathogenesis.
To identify de novo somatic variants, we validated all rare, high-
quality, protein-altering variants with AAF <40% (see Supple-
mental Experimental Procedures). Although NGS identified many
potential somatic variants, extensive validation showed some to
be false positives or germline and not bona fide somatic (Tables
S4 and S5). Potential somatic variants with a higher total read
depth (R100, Figure 1C) and higher alternate allele read depth
(R25, Figure 1D) were more likely to validate. We identified pro-
tein-altering somatic variants in this 78 gene targeted panel in
two ASD cases (Figure 2A; Table S6), with no protein-altering
somatic variants identified in control brains even after extensive
validation. Case UK20244, a 16-year-old male with ASD, harbors
a somatic missense variant inSETD2, predicted to be deleterious,
present in frontal cortex but undetectable in cerebellum (Figure 2B
and 2C), which may have contributed to his ASD symptoms and
death. Case 5278, a 15-year-old female with ASD, harbors a so-
matic splice site mutation in SCN1A, present across brain and in
nonbrain tissues at relatively high AAF (Figures 2D and 2E). We
confirmed the mosaic nature of this high AAFmutation by fluores-
cent-activated nuclear sorting (FANS), using antisera to NeuN to
separate neuronal and nonneuronal nuclei from the prefrontal cor-
tex, followed by multiple displacement amplification of single cell
genomes (Dean et al., 2001; Evrony et al., 2012). Genotyping
genome-amplified DNA from single nuclei confirmed that the mu-
tation was mosaic, with 93% ± 1.6% of cells (corrected for allelic
Figure 2. Regional Distribution of Somatic Mutations and Transcriptomic Analysis of ASD Brains
(A) Protein-altering somatic mutations in ASD (5278, UK20244), suspected ASD (967), Social Anxiety Disorder (5378), or Fragile X premutation (5006) brain. Blue
indicates brain regions tested where the mutation was detected, red indicates brain region tested where the mutation was not detected, and gray indicates
regions not tested. Arrows show approximate location of the sample tested.
(B–E) Detection and validation of protein-altering somatic mutations in ASD brains. Each panel depicts representative NGS reads, Sanger sequencing trace from
bulk brain tissue, and Sanger sequencing traces from individual clones following subcloning for case UK20244, mutation in SETD2, (B) PFC, and (C) CER; case
5278, mutation in SCN1A, (D) PFC, and (E) CER. In addition, (D) depicts single nuclei Sanger sequencing traces for case 5278, mutation in SCN1A, PFC.
(legend continued on next page)
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Table 2. Syndromic ASD Cases Suggested by Genotype-Phenotype Correlation
Case Gender Age Cause of Death Mutation Associated Syndrome Clinical Symptoms
797 M 9 Drowning ADNP Ms,
PQBP1 Ms
HVDAS,
RENS1, ID (Redin et al., 2014)
Language and developmental
delay, ADD, mild hypotonia
AN01570 F 18 SUDEP PTEN LOF Cowden syndrome (Tan
et al., 2011), autism with
macrocephaly
Large brain size noted at autopsy,
epilepsy
AN16641 M 9 SUDEP ARID1B Ms,
CACNA1C Ms,
SLC6A8 LOF
MRD12
(Timothy syndrome),
CCDS1
FH seizures and speech delay, febrile
seizures from 3 years, language delay,
hyperactivity, ID, multiplex
developmental disorder
5278 F 15 Drowning,
seizure
disorder
CACNA1H Ms,
SCN1A LOF
Epilepsy susceptibility;
Dravet syndrome, GEFSP2,
FEB3A (Fujiwara et al., 2003;
Depienne et al., 2010; Allen
et al., 2013)
Progressed from febrile seizures in
infancy to nonfebrile and generalized
tonic-clonic seizures
AN16115 F 11 Drowning,
seizure
disorder
SCN1A Ms Dravet syndrome (Gaily
et al., 2013), GEFSP2,
FEB3A
FH seizures and neuropsychiatric
disease, progressed from febrile
seizures in infancy to febrile,
tonic-clonic, and potentially myoclonic
seizures, mild ID, hyperlexia
AN09714 M 60 Pancreatic
cancer
SCN2A LOF
(SGSM3 Ms
predicted to be
benign)
EIEE11, BFIS3 Seizures from 3 years old, likely episode
of status epilepticus, delayed motor
milestones, ID
Details on cases in which medical records and syndromes associated with mutated genes suggest syndromic ASD diagnoses. ADD, attention deficit
disorder; BF1S3, seizures, benign familial infantile, 3; CCDS1, cerebral creatine deficiency syndrome 1; EIEE11, epileptic encephalopathy, early infan-
tile, 11; FEB3A, febrile seizures, familial, 3A; FH, family history; GEFSP2, epilepsy, generalized, with febrile seizures plus, type 2; HVDAS, Helsmoortel-
van der Aa syndrome; ID, intellectual disability; LOF, loss-of-function; MRD12, mental retardation, autosomal dominant 12; Ms, missense; RENS1,
Renpenning syndrome; and SUDEP, sudden unexplained death in epilepsy.dropout; see Experimental Procedures) harboring the mutation
and the remainder not carrying the mutation (Figure 2D). This mu-
tation has been previously reported in epileptic encephalopathies
(Allen et al., 2013; Depienne et al., 2010; Fujiwara et al., 2003), and
indeedcase5278sufferedgeneralizedepilepsy inaddition toASD.
While we focused our attention on protein-altering somatic vari-
ants, we also validated a synonymous variant in CACNA1H pre-
sent in frontal cortex but not detected in cerebellum of case
5378, a 22-year-old male with Social Anxiety Disorder, and an in-
tronic variant in SLC6A4, predicted to be benign, present in cere-
bellumbut not detected in frontal cortexof case967, a 32-year-old
male with suspected autism (Figure 2A; Table S6).
Review of available medical records and OMIM identified
consistent genotype-phenotype correlations in many cases
with deleterious and loss-of-function variants (Table 2). Case
797, a 9-year-old male with autism, harbors missense mutations
in ADNP and PQBP1 predicted to be deleterious. Mutations
(mostly loss-of-function) in both genes are associated with intel-
lectual disability (ID) syndromes, and the same PQBP1missense
mutation we identified was recently reported as potentially caus-
ative in two brothers with ID (Redin et al., 2014). While medical(F) PCA plot of samples analyzed by RNA sequencing.
(G–L) Detection ofmutations in RNA-seq data. Each panel depicts representative R
(H) CER; case 5278, mutation in CACNA1H, (I) PFC and (J) CER; case 4849, muta
See also Table S6 and Table S7.
914 Neuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc.records did not indicate non-nervous system symptoms, which
are commonly seen in the associated syndromes, case 797
had language and developmental delay, attention deficit disor-
der, and mild hypotonia, suggesting the missense mutations
may contribute to a milder form of the associated syndromes.
Case AN01570, an 18-year-old female with autism, harbors a
nonsense mutation in PTEN previously reported in Cowden syn-
drome (Tan et al., 2011). She had her first seizure at age 8 and
was diagnosed with epilepsy, and her autopsy records noted
her large brain size (2,100 g at 18 years old; head circumference
measurement was not available), suggestive of autismwith mac-
rocephaly associated with PTENmutations. Case AN16641, a 9-
year-old male with autism, harbors a frameshift mutation in
SLC6A8 andmissensemutations in ARID1B andCACNA1C pre-
dicted to be deleterious. He has a family history of seizures and
speech delay, and developed febrile seizures at almost 3 years of
age. He was noted to be hyperactive and was diagnosed with
language delay, ID, and a multiplex developmental disorder.
His symptoms suggest a diagnosis of cerebral creatine defi-
ciency syndrome 1, associated with mutations in SLC6A8, and
potential contribution from ARID1B, associated with ID.NA-seq reads and read counts for case 5278, mutation inSCN1A, (G) PFC and
tion in SCN2A, (J) PFC and (L) CER. CER, cerebellum; PFC, prefrontal cortex.
Three cases harbor mutations in ion channel genes associated
with seizure disorders, and presented with symptoms sugges-
tive of epilepsy. Case 5278, a 15-year-old female with autism,
harbors a missense mutation in CACNA1H predicted to be dele-
terious and a somatic splicing mutation in SCN1A, previously re-
ported in epileptic encephalopathies, as mentioned above (Allen
et al., 2013; Depienne et al., 2010; Fujiwara et al., 2003). After
febrile seizures in early infancy, she developed nonfebrile and
generalized tonic-clonic seizures, suggestive of generalized ep-
ilepsy with febrile seizures plus type 2 (GEFSP2). Case AN16115,
an 11-year-old female with autism, harbors a missense mutation
in SCN1A predicted to be deleterious; a mutation that leads to a
different amino acid at the same position was previously re-
ported in Dravet syndrome (Gaily et al., 2013). She had a family
history of seizures and neuropsychiatric disease, and was diag-
nosed with mild ID and hyperlexia. She had her first febrile
seizure at 4.5 months old, and developed febrile, tonic-clonic,
and potentially myoclonic seizures, consistent with a SCN1A
mutation. Case AN09714, a 60-year-old male with autism and
a nonsense mutation in SCN2A, showed delayed motor mile-
stones and ID. His first seizure was at age 3, and at 15 he was
hospitalized with pneumonia and experienced seizures every
5 min for a 12 hr period, suggestive of an SCN2A-associated
syndrome like epileptic encephalopathy, early infantile, 11
(EIEE11). These three cases highlight the complex relationship
between ASD and seizures (Jeste and Geschwind, 2014). Based
on available medical records, almost half of the ASD cases had
seizures, while there was no evidence of seizures in controls.
Fragile X accounts for2%of ASD cases (Huguet et al., 2013),
and the Fragile X mutation is subject to somatic expansion (Lo-
kanga et al., 2013), so we also tested postmortem brain samples
from ASD and ten Fragile X cases for expansion of the CGG
repeat in the 50 UTR of FMR1. We did not detect unsuspected
expansion in any ASD cases, but did find mosaic expansion in
three Fragile X mutation and premutation cases (Figure S1).
Case 1421, a 69-year-old male with Fragile X, harbored amosaic
full mutation in prefrontal cortex. Case 5006, an 85-year-oldmale
diagnosedwith a premutation, harbored amosaic full mutation in
both prefrontal cortex and cerebellum. We also detected a so-
matic null mutation in CACNA1C in case 5,006 that disrupts
the start methionine, present in both prefrontal cortex and cere-
bellum (Table S6), suggesting that this mutation might contribute
to pathogenesis. Case 4664, a 71-year-old male diagnosed with
a premutation and an unspecified neurological disorder,
harbored amosaic full mutation in prefrontal cortex not detected
in cerebellum. These data show that Fragile X premutations and
mutations can show somatic instability in the brain, with poten-
tially distinct effects in different brain regions.
To test if mutations were detectable in RNA and hence affect
the transcriptome, we performed RNA-sequencing (RNA-seq)
on total RNA with acceptable RNA integrity (RINR5) extracted
from prefrontal cortex and cerebellar samples of ASD cases
with protein-altering somatic mutations and/or sodium channel
mutations. The ASD cases were compared to matched (age
and sex) neurotypical controls (Table S1). After quality control,
batch correction, and quantile normalization (see Supplemental
Experimental Procedures), the expression values for protein
coding genes were calculated. Consistent with previous findings(Kang et al., 2011), principal component analysis (PCA)
confirmed that both ASD and control PFC and CER samples
have distinctive transcriptional profiles. PCA also revealed that
the ASDPFC andCER samples clustered based on their regional
identity and not the disease state (Figure 2F), indicating that
changes in the transcriptome associated with ASD are smaller
than global transcriptional differences between the two analyzed
regions.
RNA-seq data analysis confirmed the presence of several
germline and somatic mutations in the ASD cases (Figures 2G–
2L). The germline CACNA1H and somatic SCN1A mutations
were detected in case 5278, and the germline SCN2A mutation
was detected in case 4849. Low gene expression, low read
depth in RNA-seq, and/or potential destabilization of RNA by
the mutation might contribute to instances where mutant alleles
were not detected (e.g., Figure 2H). To further elucidate tran-
scriptomic differences, we identified genes that exhibited the
highest fold differences in expression between ASD and control
samples (see Supplemental Experimental Procedures). As each
case sample had distinct mutations and there were no biological
replicates, each case sample was compared with two control
samples and only genes that had an absolute fold change of 2
and were changed in the same direction between case and
both control samples were considered (Table S7). GO enrich-
ment analysis identified neuron and synapse-related annotation
clusters (data not shown), but larger sample sizes would be
required to fully characterize global effects of these mutations
on transcriptome.
DISCUSSION
Our analysis provides a unique resource of genetically charac-
terized, publically available human postmortem ASD brains for
functional studies, and supports a heterogeneous model of
ASD risk, where germline and/or de novo somatic mutations
contribute on a case-by-case basis. In many cases, we identify
a single variant predicted to be deleterious or loss-of-function,
including four independent variants in SCN2A, currently one of
the strongest ASD candidate genes (Hoischen et al., 2014).
Similarly to previous studies (O’Roak et al., 2011), we also
identify several ASD cases with multiple germline variants pre-
dicted to be deleterious. As discussed above, case AN16641
harbors a frameshift mutation in SLC6A8 and missense vari-
ants in ARID1B and CACNA1C predicted to be deleterious,
and case 797 harbors missense variants in ADNP and
PQBP1 predicted to be deleterious. In addition, case
AN00090 harbors a germline missense variant in SETD2 pre-
dicted to be deleterious and a previously identified 15q deletion
consistent with her diagnosis of Angelman syndrome (Wintle
et al., 2011). Finally, we identify a case with a somatic mutation
and a case with a germline and somatic variant: case UK20244
harbors a somatic missense variant in SETD2 predicted to be
deleterious, and case 5278 harbors a somatic splice site muta-
tion in SCN1A and a germline missense variant in CACNA1H
predicted to be deleterious. These cases underscore the com-
plex genetic architecture of ASD, and the need for detailed
phenotypic information to aid interpretation of identified ge-
netic variants.Neuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc. 915
Despite targeting only the best-validated ASD genes, we iden-
tified two ASD and one Fragile X premutation case with protein-
altering somatic mutations, providing evidence that somatic
mutations can occur in ASD, though the overall contribution of
somatic mutations to ASD risk cannot yet be defined. We
observed a somatic mutation that likely occurred early in embry-
onic development, present across the brain and nonbrain tissues
(SCN1A), as well as somatic mutations that likely occurred later,
after separation of the three germ layers and even after separa-
tion of the forebrain, midbrain, and hindbrain. Hence, somatic
mutations that are undetectable in current clinical assays using
blood-derived DNA could be important mediators of disease
expression or penetrance and modify germline variants. The
abnormal ‘‘patches’’ observed in the prefrontal and temporal
cortex of some autism cases (Casanova et al., 2013; Stoner
et al., 2014) may represent visible consequences of somatic mu-
tations, and it will be important to understand how the cell type
and brain region in which a somatic mutation occurs modifies
its effect on phenotype. With our small sample size and focused
gene list, we did not detect a significant burden of rare protein-
altering somatic mutations in ASD cases compared to controls
(p = 0.5, two-tailed Fisher’s exact test). Somatic mutations
may occur in genes not targeted by our panel, since we only
studied genes implicated in ASD via germline mutations. Other
more severe mutations, such as chromosome trisomies or acti-
vating AKT3 mutations, can be tolerated in the mosaic state
while being lethal in the germline (Poduri et al., 2012, 2013).
Larger sample sizes examined with high-coverage (R2003)
sequencing will be needed to further assess the full contribution
of somatic mutations to ASD and other neuropsychiatric dis-
eases, like schizophrenia, where germline risk mutations have
been slower to emerge.
EXPERIMENTAL PROCEDURES
Human Tissue and DNA Samples
Research performed on deidentified postmortem human specimens was
approved by the institutional review boards of Boston Children’s Hospital
and Yale School of Medicine. Case details are available in Table S1.
DNA Extraction and Targeted Sequencing
Brain DNA was extracted using the QIAamp DNA Mini kit (QIAGEN) and
libraries prepared using a custom Haloplex Target Enrichment Kit (Agilent) ac-
cording to the manufacturer’s protocols. We performed sequencing on MiSeq
sequencers (Illumina). Further details on DNA sequencing and analysis are
available in the Supplemental Experimental Procedures. Targeted sequencing
data is deposited in NDAR Collection 2029.
Variant Validation
Rare and protein-altering (nonsynonymous, nonsense, splice site, frameshift,
and insertion-deletion) variants in the target genes were validated using
Sanger sequencing. For potential somatic variants, the original DNA was
amplified using polymerase chain reaction (PCR), subcloned into a TOPO TA
vector (Invitrogen), and transformed into TOP10 chemically competent
E. coli cells (Invitrogen); multiple clones were isolated and sequenced to quan-
tify the degree of mosaicism independently of the NGS platform.
Fragile X Analysis
CGG repeat assay was performed using the AmplideX FMR1 PCR Reagents
(Asuragen) and analyzed using GeneMapper Software (Life Technologies) ac-
cording to the manufacturer’s protocol.916 Neuron 88, 910–917, December 2, 2015 ª2015 Elsevier Inc.Single Nuclei Analysis
Isolation of single neuronal and nonneuronal nuclei using fluorescence-acti-
vated nuclear sorting (FANS) with antisera to NeuN, and single-cell, whole-
genome-amplification using multiple displacement amplification (MDA)
(Dean et al., 2001) were performed as described previously (Evrony et al.,
2012). Single nuclei from the prefrontal cortex of case 5278 were isolated,
amplified, and sequenced for the splicing mutation in SCN1A using PCR
(GoTaq Hot Start DNA Polymerase, Promega). Sequencing analysis to calcu-
late the number of cells with the mutation, taking into account allelic dropout,
was performed as described previously (Evrony et al., 2012).
RNA Extraction and Sequencing
Total RNA was extracted using mirVana kit (Ambion) with some modifications
to the manufacturer’s protocol, and we prepared libraries using TruSeq
Stranded Total RNA with Ribo-Zero Gold Kit (Illumina) according to the man-
ufacturer’s protocol. We performed sequencing on HiSeq 2000 sequencer
(Illumina). Further details on RNA sequencing and analysis are available in
the Supplemental Experimental Procedures.
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